Eli Lilly

September 11, 2024 4:36 PM

Novo Nordisk experimental obesity pill has mild-to-moderate side effects in early trial

Novo Nordisk said on Wednesday that its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects. The maker of blockbuster drugs Wegovy and Ozempic said in March that a Phase I trial of the pill version of amycretin showed participants lost up to 13.1% of their weight after 12 weeks, prompting shares to surge more than 8%. That compared to weight loss of about 6% after 12 weeks and 15% after 68 we...

August 15, 2024 4:07 PM

Doctors struggle to get Wegovy for older Americans with heart disease

Older Americans are having little success getting prescriptions for weight-loss drug Wegovy covered by Medicare despite the federal healthcare program's decision to pay for patients with obesity at risk of heart disease, according to their doctors. In interviews with Reuters, seven obesity and heart disease specialists from various parts of the United States said their prescriptions for the Novo Nordisk drug have been denied repeatedly by the healthcare companies that administer Medicare drug b...

August 1, 2024 5:23 PM

Lilly says weight loss drug cut heart failure risk by 38% in trial

Trial results show Eli Lilly's weight loss drug Zepbound reduces the risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure, the company said on Thursday as it continues to build a case for the medication's wider health benefits. The drug, also known as tirzepatide, reduced the risk of a composite of heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death by 38% compared to a placebo. The trial enrolle...

July 31, 2024 7:17 PM

Benefit of Eisai and Biogen’s Alzheimer’s drug increases over time, studies suggest

The benefit of Eisai and Biogen's Alzheimer's drug Leqembi in patients with early-stage Alzheimer's appears to increase with continued use with no new safety issues, according to three-year data presented at an Alzheimer's meeting on Tuesday. In the companies' pivotal clinical trial, Leqembi reduced cognitive decline by 27% after 18 months - data that supported the drug's approval last year. The new study looked at how the drug performed in about 95% of trial patients who continued on the trea...

July 11, 2024 7:32 PM

Pfizer moves forward with once-daily weight-loss pill

Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday, after scrapping a twice- daily version of the drug late last year. The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to injections. Some analysts expect the weight-loss drug market, currently dominated ...